Joint Programming Initiative on Neurodegenerative Diseases: The Next Challenges

Prof. Philippe AmouyelChair, JPND Management Board

Joint Programming as a response to societal challenges

Alzheimer’s and Neurodegenerative Diseases in Europe

Number of cases Societal costs (€)

2010 6,000,000 72,000,000,000

2040 12,000,000 144,000,000,000

A major societal challenge for the

coming years

Alzheimer’s

The JPND goals

To tackle the challenge of Alzheimer’s and other neurodegenerative diseases*, the goals of the JPND Research Strategy are:

* Alzheimer’s disease and other dementias (AD), Parkinson’s disease (PD) and PD-related disorders, Prion disease, motor neurone diseases (MND), Huntington’s disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)

• To develop new treatments and preventive strategies

• To improve health and social care approaches

• To raise awareness and de-stigmatise neurodegenerative disorders

• To alleviate the economic and social burden of these diseases

JPND Mapping 2011

from www.jpnd.eu

JPND - Clearing Steps

• The Foundations

• Agree on a Common Vision

• Build Trust

• Define Terms of Reference

• Structure the Governance

• Working Together

• The Strategic Research Agenda

• The Implementation

• Towards Sustainability

Governance

27 countries

ManagementBoard

ExecutiveBoard

Scientific Advisory

Board

JumpaheadSteering

Committee

WP2WP1 WP3 WP4 WP5

JPND Research Strategy (SRA)

• What is it?• A holistic ‘roadmap’ for future EU-wide activity and investment

• Not a review of the field, not a list of calls for proposals

• Launched Feb 7th, 2012• 5 research priorities, 9 enabling activities

• Delivery has taken into account• SAB recommendations

• Outputs from 4 scientific/strategic workshops• National and European portfolios

• Mapping exercise of National and European programmes• Broad consultation with stakeholder groups

• Both Online and Offline

A European Challenge

“The answers to these challenges will be found in science and research. This Research Strategy comes not a moment too soon. It provides a much-needed framework for European-level coordination and investment in neurodegenerative disease research.”

Mrs Máire Geoghegan-Quinn EuropeanCommissioner for Research, Innovation and ScienceLaunch of the Research Strategy of JPNDBrussels, 7 February 2012

Next Steps

• The JPI must have clear and quantifiable scientific objectives to propose• The SRA alone is not sufficient• It is only a holistic roadmap• An implementation plan is compulsory

• Objectives must be in-line with the scientific strategy of each country • Some countries have their own National Plan• Others need to build one

The Implementation Plan

• Create list of priorities from JPND Research Strategy proposals

• Organise thematic working groups

• Create list of opportunities suited for implementation

• Organise specific task forces

• Stimulate and align National Plans

• Set action groups for specific priorities and encouraging collaborations

• Support implementation

Some achievements

• Creation of stable management structure with efficient procedures

• Mapping exercise and associated public database

• JPND Joint Transnational Calls:

• One in 2011 for €15M ; Two in 2012-2013 for €25M

• Centres of Excellence in Neurodegeneration program:

• 2011 for €6M ; in 2012-13 for €8M

• Opening up to Third Countries:

• Canada already, on-going discussions with US

The next Challenges

• To implement over time

• To partner with EU

• To partner with industry

• To ensure JPND sustainability

To implement over time

• Developing attractive programs

• Easier when a National Plan already exists

• Always « a la carte »

• Need for synchronisation of funding decisions in each country (yearly basis)

• Strengthing decisions by signing Memorandum of Understanding

• Importance of phasing and overlap

• Diversity of the tools

To partner with EU

• Establish a programme of co-investment

• Work towards a sustained increased of the investment amongst JPND partners

• Leverage the value of investments and resources at both national and European Commission level, to the benefit of Europe

Examples:•Synergy between JPND actions and H2020 programme•Linking national plans through actions engaging national infrastructures•Development and long term sustainability of European cohorts•Unlocking national capability on fellowship program

To partner with Industry

• Participation in the Research Strategy delivery

• Enlarge the contacts (pharma, device, IT, diagnosis, imaging, welfare technologies, AAL, …)

• Ongoing discussions with IMI

• Not a single mechanism to interact for companies• access to infrastructures and clinical networks• associate in JPND calls• set up an educational program

To ensure JPND sustainability

• JPND is supported by the CA Jumpahead

• Improve / achieve efficiency

• Provide points of influence of key stakeholders

• Inclusive of member states interest

• Permanent full time senior management resources

• Cash / in-kind contributions from member states

• Legal structure

Joining forces to fight neurodegenerative diseases

‘We hope that JPND will be a successful pilot for research into other challenges, as well as lead to a reduction in the burden of neurodegenerative diseases.’

www.thelancet.com/neurology Vol 12 February 2013, Editorial p119

Keep up to date

• Visit the JPND website:• http://www.neurodegenerationresearch.eu• http://www.jpnd.eu

• Search our Mapping Database

• Sign up to the JPND News Feeds

• E-mail us: secretariat@jpnd.eu

• Follow us on Twitter: @JPNDEurope